The following video is part of our "Motley Fool Conversations" series, in which technology editor/analyst Andrew Tonner and health-care editor/analyst David Williamson discuss topics across the investing world.
In this installation of our popular article series, Andrew and David sit down to talk about one dividend stock they like and one worth avoiding. David discusses drug royalty company PDL BioPharma, while Andrew talks about chip making powerhouse Intel. With dividend investing all the rage at present, investors need to know exactly what they're buying before they invest. Listen on to find out which stock deserves some love and you're better off passing on.
David Williamson and Andrew Tonner have no positions in the stocks mentioned above. The Motley Fool owns shares of Intel. Motley Fool newsletter services recommend Elan. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.